Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 3;15(3):e70146.
doi: 10.1002/pul2.70146. eCollection 2025 Jul.

How Is Pulmonary Hypertension Characterised and Treated in Children With Trisomy 21? Observations From the TOPP Registry (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension)

Tilman Humpl  1 , Rolf M F Berger  2 , Damien Bonnet  3 , Maurice Beghetti  4 , Dunbar Ivy  5 ; TOPP Investigators
Affiliations

How Is Pulmonary Hypertension Characterised and Treated in Children With Trisomy 21? Observations From the TOPP Registry (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension)

Tilman Humpl et al. Pulm Circ. .

Abstract

Pulmonary hypertension is common in children with Trisomy 21, frequently with multifactorial aetiologies. Registry data provide better understanding of disease development, diagnostic workup and treatment patterns in children with Trisomy 21. TOPP (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension) is a centre-based, comprehensive registry. Patients aged between 3 months and 18 years at time of diagnosis were eligible if they met predefined haemodynamic criteria. Demographic data, clinical symptoms at presentation, diagnostic tools, etiology, hemodynamic data, treatment, and follow-up were collected from the data base. Differences between the Trisomy 21 group and the non-Trisomy 21 group were analysed by the non-parametric Mann-Whitney test. Categorical variables were compared using the chi-squared test, or Fisher's exact test in the case of low expected frequencies. Out of 531 children in the registry, 62 patients (11.7%) were diagnosed with Trisomy 21. Compared to children without Trisomy 21, those with Trisomy 21 were younger at diagnosis, and had more often an associated congenital heart disease. Clinical symptoms at diagnosis were similar in children with or without Trisomy 21. However, those with Trisomy 21 presented less frequently with dyspnea with exertion, but more frequently with cyanosis, either at rest or with exertion. A comprehensive diagnostic workup in all children with Trisomy 21 was not done. Children with Trisomy 21 had lower mean pulmonary artery pressure (median 50 mmHg, IQR 38-62) and similar indexed pulmonary vascular resistance (median 11.5 WU.m2, IQR 7.4-18.4) compared to patients without Trisomy 21. Children with Trisomy 21 were treated less frequently with targeted therapies for pulmonary arterial hypertension and received less combination therapy. In children with Trisomy 21 and pulmonary hypertension, early systematic diagnostic work up is essential to obtain the correct underlying pathology and guides to appropriate treatment.

Keywords: Trisomy 21; lung disease; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

T.H. declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The M3C‐Necker contracts with Actelion, Bayer, Novartis, MSD, and Lilly for DB to perform consultant activities and to participate in steering committees for clinical trials. M.B. has received grants from and contracted as consultant for Actelion and Bayer‐Schering; and served as a consultant and participated in the steering committee for Actelion/Janssen, Acceleron, AOP, Bayer‐Schering, GlaxoSmithKline, and Eli Lilly, The University of Colorado contracts with Acceleron, Actelion/Janssen, Altavant, Bayer, Gilead, Gossamer Bio, Lilly, MSD and United Therapeutics for DI to be a consultant. The University Medical Center Groningen contracts with Actelion, GlaxoSmithKline, MSD, and Lilly for R.B. to perform consultant activities and to participate in steering committees for clinical trials.

Figures

Figure 1
Figure 1
Patient survival (endpoint death all causes) by Trisomy 21. All PH‐confirmed patients. No significant difference in survival (log rank test, p = 0.308).
Figure 2
Figure 2
Patient survival (endpoint death all causes) by Trisomy 21, APAH‐CHD patients only. No significant difference in survival (log rank test, p = 0.989).
See this image and copyright information in PMC

References

    1. Loane M., Morris J. K., Addor M. C., et al., “Twenty‐Year Trends in the Prevalence of Down Syndrome and Other Trisomies in Europe: Impact of Maternal Age and Prenatal Screening,” European Journal of Human Genetics 21 (2013): 27–33. - PMC - PubMed
    1. Heinke D., Isenburg J. L., Stallings E. B., et al., “Prevalence of Structural Birth Defects Among Infants With Down Syndrome, 2013–2017: A US Population‐Based Study,” Birth Defects Research 113 (2021): 189–202. - PMC - PubMed
    1. Roizen N. J. and Patterson D., “Down's Syndrome,” Lancet 361 (2003): 1281–1289. - PubMed
    1. Bush D., Galambos C., Ivy D. D., Abman S. H., Wolter‐Warmerdam K., and Hickey F., “Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children With Down Syndrome,” Journal of Pediatrics 202 (2018): 212–219.e2. - PubMed
    1. Espinola‐Zavaleta N., Soto M. E., Romero‐Gonzalez A., et al., “Prevalence of Congenital Heart Disease and Pulmonary Hypertension in Down's Syndrome: An Echocardiographic Study,” Journal of Cardiovascular Ultrasound 23 (2015): 72–77. - PMC - PubMed

LinkOut - more resources